ヘルクロン440mg注射剤

ヘルクロン440mg注射剤 (Herukuron 440mg Injection) is a pharmaceutical product containing the active ingredient Eculizumab. Eculizumab is a monoclonal antibody that works by inhibiting the complement system, a part of the immune system. Specifically, it targets and binds to the complement protein C5, preventing its cleavage into pro-inflammatory fragments C5a and C5b. This blockade of the terminal complement cascade helps to reduce the destruction of red blood cells and other cellular damage mediated by the complement system.

ヘルクロン440mg注射剤 is indicated for the treatment of certain rare and serious conditions. These include paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening blood disorder characterized by the destruction of red blood cells, and atypical hemolytic uremic syndrome (aHUS), a rare genetic disorder that causes blood clots to form in small blood vessels throughout the body, particularly in the kidneys.

The usual dosage of ヘルクロン440mg注射剤 is administered intravenously by a healthcare professional. The specific dosage and frequency will depend on the patient’s condition and response to treatment. It is crucial to follow the prescribed treatment regimen precisely. Potential side effects may include headache, nausea, vomiting, diarrhea, and an increased risk of meningococcal infections. Patients receiving eculizumab are typically vaccinated against meningococcal disease. Storage instructions should be followed as per the manufacturer’s guidelines, usually involving refrigeration.